MorphoSys (ETR:MOR) has been assigned a €114.00 ($132.56) price target by stock analysts at Goldman Sachs Group in a research report issued on Friday. The brokerage currently has a “neutral” rating on the stock. Goldman Sachs Group’s price target points to a potential upside of 12.20% from the stock’s current price.
Several other equities analysts also recently issued reports on MOR. Independent Research set a €105.00 ($122.09) price objective on shares of MorphoSys and gave the company a “neutral” rating in a report on Thursday, September 27th. Royal Bank of Canada set a €65.00 ($75.58) price objective on shares of MorphoSys and gave the company a “sell” rating in a report on Monday, October 1st. JPMorgan Chase & Co. set a €110.00 ($127.91) price objective on shares of MorphoSys and gave the company a “buy” rating in a report on Monday, October 1st. Oddo Bhf set a €110.00 ($127.91) target price on MorphoSys and gave the company a “buy” rating in a research report on Thursday, October 11th. Finally, Commerzbank set a €107.00 ($124.42) target price on MorphoSys and gave the company a “neutral” rating in a research report on Tuesday, November 6th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of €102.60 ($119.30).
MOR opened at €101.60 ($118.14) on Friday. MorphoSys has a 52-week low of €49.63 ($57.71) and a 52-week high of €88.10 ($102.44).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
See Also: How mutual funds make money
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.